Abbott Laboratories (ABT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Abbott Laboratories stock (ABT) is currently trading at $104.83. Abbott Laboratories PE ratio is 28.05. Abbott Laboratories PS ratio (Price-to-Sales) is 4.08. Analyst consensus price target for ABT is $132.64. WallStSmart rates ABT as Underperform.
Abbott Laboratories (ABT) stock price prediction for 2030: Base case $67.97. Bull case $84.96. Bear case $50.98. See full ABT 2030 price forecast and methodology on WallStSmart.
- ABT PE ratio analysis and historical PE chart
- ABT PS ratio (Price-to-Sales) history and trend
- ABT intrinsic value — DCF, Graham Number, EPV models
- ABT stock price prediction 2025 2026 2027 2028 2029 2030
- ABT fair value vs current price
- ABT insider transactions and insider buying
- Is ABT undervalued or overvalued?
- Abbott Laboratories financial analysis — revenue, earnings, cash flow
- ABT Piotroski F-Score and Altman Z-Score
- ABT analyst price target and Smart Rating
Abbott Laboratories
📊 No data available
Try selecting a different time range
ABT Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Abbott Laboratories (ABT)
ABT trades 316% above its Graham fair value of $25.23, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Abbott Laboratories (ABT) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, institutional own.. Concerns around revenue growth and eps growth. Fundamentals are solid but monitor weak areas for improvement.
Abbott Laboratories (ABT) Key Strengths (3)
82.06% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $22 kept per $100 revenue
Supporting Valuation Data
Abbott Laboratories (ABT) Areas to Watch (7)
Earnings declining -80.90%, profits shrinking
Revenue growing slowly at 4.40% annually
Premium valuation at 4.1x annual revenue
Premium pricing at 3.5x book value
Moderate profitability with room for improvement
Growth is fairly priced, not cheap, not expensive
Decent profitability, keeps $15 per $100 revenue
Supporting Valuation Data
Abbott Laboratories (ABT) Detailed Analysis Report
Overall Assessment
This company scores 51/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 3.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap, Operating Margin. Profitability is solid with Operating Margin at 21.60%.
The Bear Case
The primary concerns are EPS Growth, Revenue Growth, Price/Sales. Some valuation metrics including PEG Ratio (1.52), Price/Sales (4.08), Price/Book (3.52) suggest expensive pricing. Growth concerns include Revenue Growth at 4.40%, EPS Growth at -80.90%, which may limit upside. Profitability pressure is visible in Return on Equity at 13.00%, Profit Margin at 14.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 13.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 4.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Market Cap) and negatives (EPS Growth, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ABT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ABT's Price-to-Sales ratio of 4.08x trades at a 36% premium to its historical average of 2.99x (94th percentile). The current valuation is 8% below its historical high of 4.43x set in Mar 2026, and 214% above its historical low of 1.3x in Jan 2013.
WallStSmart Analysis Synopsis
Data-driven financial summary for Abbott Laboratories (ABT) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Abbott Laboratories is a strong growth company balancing expansion with improving profitability. Revenue reached 44.3B with 440% growth year-over-year. Profit margins of 14.7% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 440% YoY, reaching 44.3B. This pace significantly outperforms most MEDICAL DEVICES peers.
ROE of 1300.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Earnings fell 81% YoY while revenue grew 440%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Margin expansion: can Abbott Laboratories push profit margins above 15% as the business scales?
Growth sustainability: can Abbott Laboratories maintain 440%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Abbott Laboratories.
Bottom Line
Abbott Laboratories offers an attractive blend of growth (440% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Abbott Laboratories(ABT)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.